What Are the Ingredients in Mounjaro: The Active Drug, Inactive Components, and What Each One Does

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Mounjaro contains one active ingredient (tirzepatide) and seven inactive ingredients that stabilize the solution, control pH, and prevent bacterial growth
• The inactive ingredients (sodium chloride, sodium phosphate dibasic, and others) are pharmaceutical-grade excipients that have been used in injectable medications for decades
• Compounded tirzepatide formulations use different inactive ingredients than brand-name Mounjaro, which can affect reconstitution requirements and storage stability
• The preservative in multi-dose vials (m-cresol) allows 28-day use after first injection, while preservative-free formulations require single-use or refrigerated storage

Direct answer (40-60 words)

Mounjaro contains tirzepatide as its sole active ingredient at doses ranging from 2.5 mg to 15 mg per injection. The inactive ingredients are sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic dihydrate, m-cresol (preservative), and water for injection. These excipients stabilize the peptide, maintain physiological pH, and prevent microbial contamination.

Table of contents

1. The active ingredient: tirzepatide and what it does
2. The complete inactive ingredient list and the function of each component
3. What most articles get wrong about "fillers" in GLP-1 medications
4. How Mounjaro's formulation differs from Zepbound (same active ingredient, different inactive components)
5. Compounded tirzepatide: how the ingredient list changes
6. The preservative question: why m-cresol matters for multi-dose vials
7. Allergen and sensitivity concerns: what's actually in the vial
8. The pH buffer system and why it prevents injection site reactions
9. When inactive ingredients become the problem: rare but real sensitivities
10. The FormBlends ingredient transparency framework
11. FAQ
12. Footer disclaimers

The active ingredient: tirzepatide and what it does

Tirzepatide is a 39-amino-acid synthetic peptide that activates two receptor systems: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It's the only dual agonist approved for weight management and type 2 diabetes treatment as of 2026.

The molecular weight is 4,813.5 daltons. The peptide sequence includes a C20 fatty diacid modification that allows the molecule to bind to albumin in the bloodstream, which extends its half-life to approximately 5 days. This modification is why tirzepatide can be dosed once weekly instead of daily.

Each Mounjaro pen contains a fixed dose of tirzepatide:

• 2.5 mg per 0.5 mL (starting dose)
• 5 mg per 0.5 mL
• 7.5 mg per 0.5 mL
• 10 mg per 0.5 mL
• 12.5 mg per 0.5 mL
• 15 mg per 0.5 mL (maximum approved dose)

The tirzepatide in Mounjaro is manufactured using recombinant DNA technology in genetically modified Escherichia coli bacteria. The peptide is then purified through multiple chromatography steps to remove bacterial proteins, endotoxins, and process-related impurities. The final purity specification is greater than 95% as measured by HPLC (high-performance liquid chromatography).

The mechanism is well-established. Tirzepatide binding to GLP-1 receptors slows gastric emptying, increases insulin secretion in response to food, and reduces glucagon secretion. GIP receptor activation adds complementary effects on insulin sensitivity and fat metabolism. The combined result is reduced appetite, slower digestion, and improved glucose control (Frias et al., New England Journal of Medicine, 2021).

The complete inactive ingredient list and the function of each component

Mounjaro's inactive ingredients serve specific pharmaceutical functions. None are "fillers" in the sense of inert bulk. Each has a job.

Ingredient	Function	Concentration	Safety profile
Sodium chloride	Isotonicity agent	6.4 mg/mL	Physiological salt; same concentration as normal saline
Sodium phosphate dibasic heptahydrate	pH buffer (alkaline component)	0.82 mg/mL	GRAS (Generally Recognized as Safe); used in IV fluids
Sodium phosphate monobasic dihydrate	pH buffer (acidic component)	0.11 mg/mL	GRAS; balances dibasic phosphate to achieve target pH
m-Cresol	Antimicrobial preservative	4.5 mg/mL	Phenolic preservative; standard in multi-dose insulin and GLP-1 pens
Water for injection	Solvent	To volume	USP-grade sterile water

Sodium chloride (table salt in pharmaceutical grade) adjusts the osmolarity of the solution to match human blood plasma (approximately 290 mOsm/kg). Injecting a solution with mismatched osmolarity causes stinging, tissue irritation, and potential cell damage at the injection site. The 6.4 mg/mL concentration makes Mounjaro isotonic, which is why most patients report minimal injection discomfort.

Sodium phosphate dibasic and monobasic form a buffer system that holds the solution pH between 7.0 and 8.0. Tirzepatide is a peptide, and peptides degrade rapidly outside their stable pH range. Acidic pH (below 6.0) causes aggregation and loss of potency. Alkaline pH (above 9.0) causes hydrolysis of peptide bonds. The phosphate buffer prevents pH drift during the 28-day use window after first injection.

m-Cresol (meta-cresol, 3-methylphenol) is a preservative that prevents bacterial and fungal growth in multi-dose vials and pens. Once you puncture a vial or use a pen for the first injection, the sterile seal is broken. Without a preservative, bacteria from skin or air could colonize the solution. m-Cresol kills microbes on contact and remains active for 28 days, which is why Mounjaro pens are labeled for 28-day use after first injection. The concentration (4.5 mg/mL) is the same used in insulin pens and has a 40-year safety record in diabetic patients who inject daily.

Water for injection is not tap water or distilled water. It's USP-grade water that has been purified through reverse osmosis, deionization, and sterilization. It contains no endotoxins (bacterial cell wall fragments that cause fever and inflammation) and no particulates larger than 0.2 microns.

The formulation is designed for subcutaneous injection. It's not suitable for intravenous, intramuscular, or oral use. The pH, osmolarity, and preservative concentration are optimized specifically for subcutaneous tissue.

What most articles get wrong about "fillers" in GLP-1 medications

The most common error in patient-facing content about Mounjaro ingredients is calling the inactive ingredients "fillers" and implying they're unnecessary or potentially harmful additives included to bulk up the product or cut costs.

This is wrong on every level.

Tirzepatide is a peptide. Peptides are fragile molecules that degrade in the presence of light, heat, oxygen, pH changes, and microbial contamination. You cannot inject pure tirzepatide powder dissolved in tap water. It would aggregate into useless clumps within hours, and the injection would be painful and potentially dangerous.

The inactive ingredients are pharmaceutical excipients, not fillers. Each one serves a stability, safety, or usability function:

• Buffers prevent pH drift that would destroy the peptide.
• Isotonicity agents prevent tissue damage and pain at the injection site.
• Preservatives prevent bacterial contamination in multi-dose containers.
• Solvent (water for injection) provides a sterile, pyrogen-free medium.

The idea that you could formulate a "cleaner" version of Mounjaro by removing these ingredients is pharmacologically nonsensical. What you'd get is an unstable, contaminated, painful injection that loses potency within days.

The second common error is assuming all GLP-1 medications have identical inactive ingredients. They don't. Ozempic (semaglutide) uses a different buffer system (disodium phosphate dihydrate plus propylene glycol). Wegovy uses the same base as Ozempic but in a different concentration. Zepbound (also tirzepatide) uses the same inactive ingredients as Mounjaro because it's the same manufacturer, but compounded tirzepatide from third-party pharmacies uses entirely different excipient profiles depending on the compounding pharmacy's formulation.

The inactive ingredients matter clinically. Patients who develop injection site reactions on one GLP-1 medication sometimes tolerate a different one better, not because the active ingredient changed but because the excipient profile changed. A patient sensitive to m-cresol will react to Mounjaro but may tolerate a preservative-free compounded formulation.

How Mounjaro's formulation differs from Zepbound (same active ingredient, different inactive components)

Mounjaro and Zepbound both contain tirzepatide as the active ingredient. Both are manufactured by Eli Lilly. The inactive ingredient lists are identical because they use the same base formulation.

The difference is indication and approved dosing:

• Mounjaro is FDA-approved for type 2 diabetes at doses from 2.5 mg to 15 mg.
• Zepbound is FDA-approved for chronic weight management at doses from 2.5 mg to 15 mg.

The tirzepatide molecule is the same. The excipients are the same. The manufacturing process is the same. The pens are the same physical device. The only differences are the label, the indication, and the insurance coding.

This is not unusual in pharmaceuticals. Prozac (fluoxetine for depression) and Sarafem (fluoxetine for premenstrual dysphoric disorder) are the same drug with different branding. Mounjaro and Zepbound follow the same pattern.

For patients, this means: if you tolerate Mounjaro, you'll tolerate Zepbound, and vice versa. If you have an injection site reaction to one, you'll likely have the same reaction to the other. The excipient sensitivity profile is identical.

The regulatory distinction matters for insurance coverage and prescribing. The chemical distinction does not exist.

Compounded tirzepatide: how the ingredient list changes

Compounded tirzepatide is prepared by state-licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. These formulations are not FDA-approved and do not undergo the same review process as Mounjaro.

The active ingredient is tirzepatide, typically sourced from bulk peptide manufacturers in the U.S., Europe, or Asia. The purity and identity must be verified by the compounding pharmacy through certificate of analysis (CoA) and third-party testing, but the testing standards are not identical to FDA requirements for approved drugs.

The inactive ingredients vary by pharmacy. Common formulations include:

Lyophilized (freeze-dried) powder formulations:

• Tirzepatide (active)
• Mannitol (bulking agent and stabilizer)
• Trehalose or sucrose (cryoprotectant)
• Sodium phosphate buffer salts
• No preservative (single-use or requires bacteriostatic water for reconstitution)

Pre-mixed liquid formulations:

• Tirzepatide (active)
• Bacteriostatic water or bacteriostatic sodium chloride (solvent with preservative)
• Benzyl alcohol (preservative, 0.9% to 1.0%)
• Sodium chloride (isotonicity)
• Phosphate or acetate buffer

Multi-ingredient compounded formulations: Some compounding pharmacies add vitamin B12 (cyanocobalamin or methylcobalamin), L-carnitine, or other compounds to the tirzepatide formulation. These are not part of the FDA-approved Mounjaro formulation and have not been studied in combination with tirzepatide in controlled trials.

The key differences:

1. Preservative type. Compounded formulations often use benzyl alcohol instead of m-cresol. Benzyl alcohol has a different sensitivity profile. Patients allergic to m-cresol may tolerate benzyl alcohol, and vice versa.

1. Reconstitution requirement. Lyophilized compounded tirzepatide requires reconstitution with bacteriostatic water or saline before injection. Mounjaro is pre-mixed and ready to inject. Reconstitution introduces user error risk (incorrect dilution, contamination, incomplete dissolution).

1. Stability data. Mounjaro has published stability data showing potency retention for 28 days after first use when stored at 2°C to 8°C or at room temperature up to 30°C. Compounded formulations have limited or no published stability data. Most compounding pharmacies recommend use within 28 days of reconstitution, but this is based on preservative efficacy, not peptide stability testing.

1. Excipient variability. Two compounding pharmacies may use different buffers, different preservatives, and different stabilizers for the same active ingredient. This means a patient switching from one compounded source to another may experience different injection site reactions, different reconstitution behavior, or different subjective tolerability even though the tirzepatide dose is the same.

FormBlends works exclusively with U.S.-based 503B compounding pharmacies that provide CoA documentation, third-party sterility testing, and endotoxin testing for every batch. We require disclosure of all inactive ingredients and provide that information to patients and prescribers before the first prescription is filled.

The preservative question: why m-cresol matters for multi-dose vials

Preservatives are the most misunderstood component of injectable medications. Patients often ask, "Why do I need a preservative? Can't I just use a preservative-free version?"

The answer depends on whether you're using a single-dose vial or a multi-dose vial (or pen).

Single-dose vials contain no preservative. The entire contents are drawn into a syringe and injected in one use. The vial is then discarded. Because the vial is only punctured once and the contents are used immediately, there's no opportunity for bacterial contamination. Preservative-free formulations are appropriate for single-dose use.

Multi-dose vials and pens are punctured multiple times over days or weeks. Each time you insert a needle, you introduce a potential contamination route. Skin bacteria (Staphylococcus epidermidis, Staphylococcus aureus), environmental bacteria, and fungi can enter the vial through the puncture site or from airborne particles. Without a preservative, these microbes multiply in the nutrient-rich peptide solution.

Injecting a contaminated solution can cause:

• Local infection at the injection site (cellulitis, abscess)
• Systemic infection (bacteremia, sepsis in immunocompromised patients)
• Pyrogenic reactions (fever, chills) from bacterial endotoxins

Preservatives prevent this. m-Cresol at 4.5 mg/mL kills bacteria and fungi on contact and maintains antimicrobial activity for 28 days. This is why Mounjaro pens are labeled "use within 28 days of first injection" even when stored in the refrigerator. After 28 days, the preservative efficacy declines and contamination risk increases.

The 28-day window is based on USP (United States Pharmacopeia) antimicrobial effectiveness testing, which requires that a preservative system kill 99.9% of bacteria within 14 days and prevent regrowth through 28 days.

Benzyl alcohol (used in many compounded formulations) has a similar preservative profile but a different sensory experience. Some patients report more injection site stinging with benzyl alcohol than with m-cresol. Others report the opposite. The difference is individual sensitivity.

Preservative-free compounded tirzepatide is available but requires either:

• Single-use vials (discard after one injection, which increases cost and waste)
• Reconstitution with bacteriostatic water (which adds benzyl alcohol as a preservative)
• Strict refrigeration and use within 7 days of reconstitution (which limits flexibility)

There is no preservative-free multi-dose option that maintains safety and convenience. The physics of microbial contamination don't allow it.

Allergen and sensitivity concerns: what's actually in the vial

Mounjaro does not contain:

• Latex (the pen needle cap is latex-free)
• Gluten
• Dairy proteins
• Egg proteins
• Soy
• Nuts
• Shellfish
• Gelatin
• Pork or beef derivatives

The tirzepatide peptide is synthesized in bacteria, not extracted from animal tissue. The excipients are synthetic or mineral-derived (sodium salts, water). There are no animal-derived components.

m-Cresol sensitivity is rare but documented. Patients with known sensitivity to phenolic compounds (phenol, cresols, thymol) may react to m-cresol-preserved formulations. Reactions include injection site redness, itching, hives, or in rare cases systemic allergic reactions. If you have a history of reaction to insulin or other m-cresol-preserved injectables, inform your provider before starting Mounjaro.

Phosphate sensitivity is extremely rare. Sodium phosphate salts are present in nearly all processed foods and are a normal component of human blood chemistry. True phosphate allergy is not a recognized clinical entity. However, patients with severe chronic kidney disease may need to limit phosphate intake, and the small amount in a weekly injection is negligible compared to dietary sources.

Sodium sensitivity from the sodium chloride in Mounjaro is not clinically relevant. Each 0.5 mL injection contains approximately 3.2 mg of sodium, which is 0.14% of the FDA daily value (2,300 mg). For comparison, one slice of bread contains 100 to 200 mg of sodium.

The most common injection site reactions (redness, mild swelling, itching at the injection site) are not allergic reactions. They're local inflammatory responses to the injection itself (mechanical trauma, volume of fluid, subcutaneous tissue distension). These reactions are self-limited and resolve within 24 to 48 hours. True allergic reactions involve hives beyond the injection site, facial swelling, difficulty breathing, or systemic symptoms.

If you develop a severe injection site reaction (spreading redness, warmth, pus, fever), contact your provider. This may indicate infection rather than allergy.

The pH buffer system and why it prevents injection site reactions

The pH of a solution determines whether it stings when injected. Human subcutaneous tissue has a pH of approximately 7.4 (slightly alkaline). Solutions with pH far from 7.4 cause pain, burning, and tissue irritation.

Mounjaro's pH is buffered to 7.0 to 8.0, which closely matches physiological pH. This is why most patients report minimal discomfort during injection.

The buffer system uses sodium phosphate dibasic (alkaline) and sodium phosphate monobasic (acidic) in a specific ratio to achieve the target pH. This is a classic pharmaceutical buffer pair used in IV fluids, eye drops, and other injectables.

Why pH matters for peptide stability: Tirzepatide has ionizable amino acid residues (aspartic acid, glutamic acid, lysine, arginine) that gain or lose protons depending on pH. At low pH (acidic), the peptide becomes positively charged and aggregates through electrostatic attraction. At high pH (alkaline), the peptide becomes negatively charged and can undergo hydrolysis (water breaks peptide bonds).

The stable pH range for tirzepatide is 7.0 to 8.0. Outside this range, potency declines measurably within days. The phosphate buffer holds the solution in the stable range even when exposed to air (which can introduce carbon dioxide, forming carbonic acid) or temperature fluctuations.

Compounded formulations sometimes use acetate buffers instead of phosphate buffers. Acetate buffers work but have a narrower buffering range. A phosphate-buffered formulation is more forgiving of storage condition variation.

Patients who experience stinging or burning during injection of a compounded tirzepatide formulation should ask their pharmacy what buffer system is used and what the solution pH is. A pH below 6.5 or above 8.5 will cause discomfort and may indicate formulation instability.

When inactive ingredients become the problem: rare but real sensitivities

Most patients tolerate Mounjaro's excipients without issue. A small subset develops reactions to specific inactive ingredients.

m-Cresol sensitivity is the most common excipient reaction. Symptoms include:

• Persistent redness or raised welt at the injection site lasting more than 48 hours
• Itching at the injection site that worsens over hours
• Hives appearing near (but not at) the injection site
• Recurrent reactions at every injection

Management: switch to a preservative-free compounded formulation or a formulation using benzyl alcohol instead of m-cresol. The tirzepatide itself is usually not the problem.

Benzyl alcohol sensitivity (in compounded formulations) presents similarly. Some patients tolerate m-cresol but react to benzyl alcohol. The solution is switching to an m-cresol-preserved formulation (brand-name Mounjaro or Zepbound) or a preservative-free single-use formulation.

Injection site reactions that are NOT excipient sensitivity:

• Mild redness or swelling at the injection site resolving within 24 hours (normal inflammatory response)
• Bruising at the injection site (small blood vessel puncture, not allergy)
• Temporary lump or firmness under the skin (normal response to subcutaneous fluid volume)
• Itching that starts immediately and resolves within hours (histamine release from mast cells, not true allergy)

The distinction matters because true excipient sensitivity requires formulation change, while normal injection site reactions require only reassurance and proper injection technique.

If you're unsure whether a reaction is normal or concerning, take a photo of the injection site at 1 hour, 6 hours, and 24 hours after injection. Send the photos to your provider. The progression over time distinguishes normal reactions (peak at 1 to 6 hours, resolve by 24 hours) from sensitivity reactions (worsen over 24 to 48 hours).

The FormBlends ingredient transparency framework

FormBlends requires every compounding pharmacy partner to disclose:

1. Active ingredient source and purity. Certificate of analysis from the peptide manufacturer showing tirzepatide purity greater than 95% by HPLC and identity confirmation by mass spectrometry.

1. Complete inactive ingredient list. Every excipient, including preservatives, buffers, stabilizers, and solvents, with concentration ranges.

1. Preservative type and concentration. Whether the formulation uses m-cresol, benzyl alcohol, or is preservative-free, and at what concentration.

1. pH range. The target pH and acceptable range for each batch.

1. Sterility and endotoxin testing. Third-party lab results confirming sterility (no bacterial or fungal growth) and endotoxin levels below 0.5 EU/mL (USP limit for injectables).

1. Stability data or storage recommendations. Either published stability data showing potency retention over time, or conservative storage and use recommendations (e.g., "use within 28 days of reconstitution, store at 2°C to 8°C").

This information is provided to prescribers and patients before the first prescription is filled. If a patient has a known sensitivity to a specific excipient, the prescriber can select a formulation that avoids that ingredient.

The goal is informed consent. Patients should know what they're injecting and why each ingredient is present. The "trust us, it's safe" model is not acceptable for compounded medications that lack FDA review.

We see consistently across our patient population that ingredient transparency reduces anxiety about compounded formulations. Patients who understand that sodium chloride is table salt and sodium phosphate is a food-grade buffer are less likely to worry about "chemicals" in their medication. Education converts fear into informed decision-making.

FAQ

What is the active ingredient in Mounjaro? Tirzepatide, a 39-amino-acid synthetic peptide that activates GLP-1 and GIP receptors. It's the only dual agonist approved for weight management and diabetes treatment.

What are the inactive ingredients in Mounjaro? Sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic dihydrate, m-cresol (preservative), and water for injection. Each serves a specific pharmaceutical function (pH buffering, isotonicity, preservation, solvent).

Does Mounjaro contain any allergens? No. Mounjaro does not contain latex, gluten, dairy, eggs, soy, nuts, shellfish, gelatin, or animal-derived ingredients. The peptide is synthesized in bacteria, and all excipients are synthetic or mineral-derived.

What is m-cresol and why is it in Mounjaro? m-Cresol is a phenolic preservative that prevents bacterial and fungal growth in multi-dose pens. It allows safe use for 28 days after the first injection. Without a preservative, the pen would need to be discarded after a single use.

Are compounded tirzepatide ingredients the same as Mounjaro? No. Compounded formulations use different inactive ingredients depending on the pharmacy. Common differences include benzyl alcohol instead of m-cresol, different buffer systems, and the need for reconstitution with bacteriostatic water.

Can I use Mounjaro if I'm allergic to m-cresol? Probably not. m-Cresol sensitivity causes injection site reactions. If you have a known sensitivity to m-cresol or phenolic preservatives, ask your provider about preservative-free compounded tirzepatide or formulations using benzyl alcohol.

Why does Mounjaro need a buffer system? Tirzepatide degrades rapidly outside its stable pH range (7.0 to 8.0). The phosphate buffer prevents pH drift during storage and use, maintaining potency for 28 days after first injection.

Is the tirzepatide in compounded versions the same as Mounjaro? The peptide sequence is identical, but the purity, manufacturing process, and quality control are not FDA-verified for compounded versions. Compounding pharmacies source tirzepatide from bulk peptide manufacturers and must verify identity and purity through third-party testing.

Does Mounjaro contain gluten? No. None of the ingredients are derived from wheat, barley, rye, or other gluten-containing grains.

What does "water for injection" mean? Water for injection (WFI) is USP-grade sterile water that has been purified to remove endotoxins, particulates, and microbes. It's not the same as distilled water or tap water.

Can I be allergic to sodium phosphate? True sodium phosphate allergy is not a recognized clinical entity. Sodium phosphate is a normal component of blood chemistry and is present in most processed foods. Injection site reactions are almost never due to phosphate sensitivity.

Why do some patients react to Mounjaro but not compounded tirzepatide? Usually because the preservative is different. Mounjaro uses m-cresol; many compounded formulations use benzyl alcohol. A patient sensitive to one may tolerate the other.

How long do Mounjaro's ingredients stay stable? Unopened Mounjaro pens are stable until the expiration date when stored at 2°C to 8°C. After first use, the pen is stable for 28 days at room temperature (up to 30°C) or refrigerated. The 28-day limit is based on preservative efficacy, not peptide degradation.

Do I need to worry about the sodium content in Mounjaro? No. Each injection contains about 3.2 mg of sodium, which is 0.14% of the daily recommended limit. This is clinically insignificant even for patients on sodium-restricted diets.

What's the difference between Mounjaro and Zepbound ingredients? None. Both contain identical active and inactive ingredients. The only differences are the label, indication (diabetes vs weight management), and insurance coding.

Sources

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff PJ et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2022.
4. United States Pharmacopeia. General Chapter <51> Antimicrobial Effectiveness Testing. USP 44-NF 39. 2021.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
6. Thomas MK et al. Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta-cell function and insulin sensitivity in type 2 diabetes. Diabetes Care. 2021.
7. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
8. U.S. Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products. FDA Database. 2024.
9. Buse JB et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2020.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. American Society of Health-System Pharmacists. AHFS Drug Information 2024: Tirzepatide. ASHP. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.